Exelixis (EXEL) is down -15.7%, or -$6.97 to $37.42.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target lowered to $46 from $48 at Morgan Stanley
- Exelixis price target lowered to $49 from $56 at Truist
- Exelixis price target lowered to $45 from $50 at RBC Capital
- Exelixis’s Cabometyx Gains Strong Market Share in Neuroendocrine Tumors, Exceeding Expectations
- Exelixis Stock Performance: Hold Rating Amid Earnings Miss and Strategic Concerns